Advertisement

Topics

Spark Therapeutics' Vision Loss Gene Therapy Heads For EU Market

09:23 EDT 3 Aug 2017 | SCRIP

A gene therapy for inherited retinal conditions leading to blindness could be marketed in Europe in 2018, but needs to...

      

Related Stories

 

Original Article: Spark Therapeutics' Vision Loss Gene Therapy Heads For EU Market

NEXT ARTICLE

More From BioPortfolio on "Spark Therapeutics' Vision Loss Gene Therapy Heads For EU Market"

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...